Search for: "AVENTIS PHARMACEUTICALS, INC.,"
Results 21 - 40
of 219
Sort by Relevance
|
Sort by Date
30 Jan 2020, 10:49 am
In January 2019, Illinois reached a $135 million settlement with Teva Pharmaceuticals, and in October, the state reached a $242 million settlement with more than a dozen different drug makers, including Abbot Laboratories, Aventis, GlaxoSmithLine, Johnson & Johnson, McNeil, Novartis, and more. [read post]
24 Jan 2020, 10:24 am
Walgreens – In January 2019, Walgreens Boots Alliance, Inc. [read post]
1 Aug 2019, 8:30 am
Boehringer Ingelheim Corp., et al., a $150 million settlement with GlaxoSmithKline PLC, and a $190 million settlement with Aventis Pharmaceuticals, Inc. [read post]
3 Apr 2019, 5:15 am
Amphastar Pharmaceutical, Inc.,... [read post]
3 Apr 2019, 5:15 am
Amphastar Pharmaceutical, Inc., 525 F.3d 1334, 1349 (Fed.Cir.2008). [read post]
29 Jun 2018, 7:50 am
Amphastar Pharmaceuticals, Inc. [read post]
5 Feb 2018, 9:59 pm
Mylan Pharmaceuticals, Inc. v. [read post]
5 Sep 2017, 7:45 am
According to DOJ’s press release: Pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve claims that they violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid, the Justice Department announced today. [read post]
25 Aug 2017, 7:02 am
On Thursday, August 17, 2017, the Department of Justice, announced that Mylan Inc. and Mylan Specialty L.P. [read post]
25 Aug 2017, 7:02 am
On Thursday, August 17, 2017, the Department of Justice, announced that Mylan Inc. and Mylan Specialty L.P. [read post]
18 Aug 2017, 2:15 pm
Mylan Inc., et al.. [read post]
18 Aug 2017, 2:15 pm
Mylan Inc., et al.. [read post]
18 Aug 2017, 2:15 pm
Mylan Inc., et al.. [read post]
10 Oct 2016, 2:59 pm
Taxotere: The Case Against a Chemo Drug Taxotere, the marketed brand name of the drug docetaxel, is a taxane-class drug manufactured by Sanofi-Aventis Pharmaceutical. [read post]
26 Jul 2016, 8:45 pm
Zydus Pharmaceuticals (USA) Inc. 1:16-cv-00540; filed June 29, 2016 in the District Court of Delaware Plaintiffs: Genzyme Corp.; Sanofi-Aventis U.S. [read post]
3 Mar 2016, 5:19 am
Aventis Pharma, 579 F. [read post]
31 Dec 2015, 5:12 am
Ortho-McNeil-Janssen Pharmaceuticals, Inc., ___ F.3d ___, 2015 WL 8538119 (6th Cir. [read post]
29 Jul 2015, 10:00 pm
LLC and Regeneron Pharmaceuticals, Inc. filed a petition for Inter Partes Review (IPR) of the “Cabilly II” patent, U.S. [read post]
26 May 2015, 7:42 am
Claims such as in Mills, which are at loggerheads with FDA criteria for drug development, are precisely those with the most potential for making pharmaceutical manufacturers into “sitting ducks” for litigation, in this instance litigation based on extraneous genetic factors.It may well be that the coming (and to some extent existing) revolution in genetically individualized medical therapy will require changes in how drugs are evaluated, labeled, etc., but this is a… [read post]
17 May 2015, 4:00 am
” Pharmaceuticals: Amending PleadingsSanofi-Aventis v. [read post]
